Wechselwirkungen · Cibinqo
Cibinqo 50 mg film-coated tablets Cibinqo 100 mg film-coated tablets Cibinqo 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-147565 · Präparat HOS-099686
In vitro, abrocitinib is an inhibitor of CYP2C19 enzyme. Co-administration of abrocitinib 200 mg once daily with omeprazole 10 mg single dose increased the AUCinf and Cmax of omeprazole by approximately 189% and 134%, respectively, indicating that abrocitinib is a moderate inhibitor of CYP2C19 enzyme. Caution should be exercised when using abrocitinib concomitantly with narrow therapeutic index medicines that are primarily metabolised by CYP2C19 enzyme (e.g. S-mephenytoin and clopidogrel). Dose adjustment may be required for other medicines primarily metabolised by CYP2C19 enzyme in accordance with their product information (e.g. citalopram, clobazam, escitalopram and selumetinib).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): selumetinib (HOS-145424) citalopram (HOS-087802) mephenytoin (HOS-109801) clopidogrel (HOS-087927) clobazam (HOS-115305) escitalopram (HOS-129417) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-16T15:51:00Z · SHA-256 bdf6a4ed1027bc748659bcb0a96655dbad2dd1f8fd77f49e5ad43eff208cc7ff · Passage 1cca7ac459e58966385e24e3af8466ce5a47e434584b749e74a0ba583d975299 · Zeichen 2955–3645 im Abschnitt